Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor

Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer

NCT04758416 ·Status: UNKNOWN

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

NCT05541367 ·Status: RECRUITING

4FMFES-PET Imaging of ER+ Advanced Breast Cancers

NCT04824014 ·Status: RECRUITING ·Phase: PHASE2

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

NCT03768479 ·Status: UNKNOWN ·Phase: NA

Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer

NCT01986569 ·Status: COMPLETED ·Phase: PHASE3

Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

NCT03507088 ·Status: COMPLETED ·Phase: NA

[18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer

NCT07314073 ·Status: RECRUITING ·Phase: PHASE2

Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer

NCT04411966 ·Status: COMPLETED ·Phase: NA

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

NCT04883814 ·Status: UNKNOWN ·Phase: PHASE2

Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer

NCT01814449 ·Status: UNKNOWN

Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer

NCT01627704 ·Status: COMPLETED ·Phase: NA

Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer

NCT05088785 ·Status: RECRUITING ·Phase: NA

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

NCT06335069 ·Status: RECRUITING ·Phase: PHASE2

Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation

NCT03544762 ·Status: UNKNOWN ·Phase: PHASE3

FES (16α-[18F]-Fluoro-17β-estradiol)-PET: Towards a New Standard to Stage Locally Advanced and Recurrent, Estrogen Receptor Positive (ER+) Breast Cancer? Pilot Study to Compare [18F]FES-PET and [18F]FDG-PET

NCT03726931 ·Status: COMPLETED ·Phase: NA

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

NCT06557148 ·Status: RECRUITING

AR and ER Imaging in Metastatic Breast Cancer

NCT01988324 ·Status: COMPLETED ·Phase: PHASE2

F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

NCT02149173 ·Status: TERMINATED ·Phase: NA

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

NCT02398773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

[18F]FES PET/CT in Endocrine Refractory Breast Cancer

NCT02409316 ·Status: COMPLETED ·Phase: PHASE2

Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

NCT04992156 ·Status: COMPLETED

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

NCT03065712 ·Status: WITHDRAWN ·Phase: PHASE2

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

NCT05637034 ·Status: UNKNOWN ·Phase: NA

Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer

NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES

NCT03873428 ·Status: RECRUITING ·Phase: NA